Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR806-specific CAR T Cell Locoregional Immunotherapy for Pediatric CNS Tumors
NCT03638167Phase 1Completed
- Sponsor
- Seattle Children's
- Start
- Mar 2019
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of EGFR806 CAR T cells in central nervous system tumor (2 arms), sponsored by Seattle Children's. Primary endpoints: Adverse Events Assessed by CTCAE v5.0 at 6 months and Number of Successfully Manufactured and Infused Products at 28 days. Started Mar 2019; status: completed.
02
Drugs
EGFR806 CAR T cells
03
Conditions
central nervous system tumor
Beyond the preview
Go deeper on NCT03638167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638167.